Sign In
Buy CORT
$79.85
+0.140 (+0.176%)
At Close: Jun 23, 2026
Corcept Resubmits NDA for Relacorilant in Cushing's Syndrome
11:00am, Thursday, 18'th Jun 2026
CORT resubmits relacorilant NDA for Cushing's syndrome, with updated analyses and data from multiple clinical studies supporting the filing.
Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm
10:10pm, Wednesday, 17'th Jun 2026
NEW YORK, June 17, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Corcept Therapeutics Incorporated (NASDAQ: CO
Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing's Syndrome
04:28pm, Wednesday, 17'th Jun 2026
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog
Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm
09:43pm, Tuesday, 16'th Jun 2026
New York, New York--(Newsfile Corp. - June 16, 2026) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Corcept Therapeutics Incorporated
Invesco's RSPH vs. PJP: Which Health Care ETF Is the Better Fund For The GLP-1 Revolution?
04:42pm, Monday, 15'th Jun 2026
Compare portfolio strategies, cost structures, and risk profiles as two Invesco healthcare ETFs take different paths to sector exposure.
CORT Stock Rises 42% in a Month: Here's What You Should Know
01:06pm, Monday, 08'th Jun 2026
Corcept shares surge 42% in a month as relacorilant advances in Cushing's syndrome and Lifyorli approval to expand the company's revenue base.
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinol
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog
Healthcare ETFs: PJP Focuses on Pharmaceuticals, While XBI Zeroes in on Biotech
08:45am, Friday, 05'th Jun 2026
Compare risk profiles, dividend strategies, and portfolio concentration as these two healthcare ETFs take different paths to long-term returns.
State Street SPDR S&P Pharmaceuticals vs First Trust NYSE Arca Biotech: Which Is the Better ETF For Your Portfolio?
01:13pm, Thursday, 04'th Jun 2026
Explore how these two healthcare ETFs differ in diversification, sector focus, and portfolio concentration-key factors shaping their long-term investor appeal.
Biotech ETFs: Which ETF Offers Lower Fees? IBBQ or XPH?
11:16am, Thursday, 04'th Jun 2026
Compare diversification strategies and see how each ETF's unique index focus shapes risk and return for healthcare sector investors.
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog
CORT to Resubmit NDA for Relacorilant in Cushing's Syndrome, Stock Up
11:16am, Thursday, 28'th May 2026
Corcept stock jumps after the company announces plans to resubmit relacorilant's NDA for treating Cushing's syndrome.
Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing's Syndrome
08:00am, Wednesday, 27'th May 2026
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog
Wall Street Analysts Believe Corcept (CORT) Could Rally 43.32%: Here's is How to Trade
10:55am, Tuesday, 19'th May 2026
The consensus price target hints at a 43.3% upside potential for Corcept (CORT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
